KRAS and gastric cancer: On the other hand, BRAF mutations in our cohort correlated with alterations in multiple genes including the EGFR–EGFR fusion, correlated SNVs were: KRAS, FBXW7, WT1, EGFR, KDR, and ERBB3 (see Figure 3b) suggesting BRAF could be an actionable target for a subset of GC patients who also carry somatic EGFR and/or KRAS alterations.